Pulmonary Hypertension Accelerated Bayer Awards, a new program launched by Bayer US, will award up to $1 million in grants to support clinical research in pulmonary hypertension, with a focus in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Grant applications will be open to physician practitioners and nonphysicians in the United States starting May 28 through June 30, 2019. Applicants will be expected to submit letters of intent with a short proposal that will be reviewed by an independent Grants Review Committee of 6 to 8 leading medical experts. After the initial evaluation, applicants will be invited to submit a full proposal by August 31, 2019.

Related Articles

The applications can be submitted within 4 categories of clinical research:

Level 1 is appropriate for investigators wishing to conduct a single center or restricted multicenter clinical trial in <5 sites in the United States. The award value is worth up to $200,000 total, the duration is for 2 years, and the maximum number of new awards per year is 2.

Level 2 is appropriate for early to midcareer professionals working pulmonary hypertension. The award value is worth up to $150,000 total, the duration is for 2 years, and the maximum number of new awards per year is 2.

Level 3 is appropriate for fellows and will be supporting research completed within the first 2 years of the applicant’s first faculty position. The award value is worth up to $100,000 total, the duration of the award is for 2 years, and the maximum number of new awards per year is 2.

Level 4 is appropriate for allied health professionals working in pulmonary hypertension, including nurses, nurse practitioners, physiotherapists, pharmacists, and psychologists. The award value is worth up to $50,000 total, the duration of the award is for 1 to 2 years, and the maximum number of new awards per year is 2.

“The Pulmonary Hypertension Accelerated Bayer Awards is a reflection of our commitment to ensuring continued advancement in pulmonary hypertension science and care, and to the continued growth of young scientists, clinicians, and allied healthcare professionals involved in pulmonary hypertension research and education,” said Aleksandra Vlajnic, MD, Vice President of Medical Affairs at Bayer in a press release.

The deadline for the letter of intent submissions is 12:00 AM PST, June 30, 2019. The entries will be evaluated on “significance, investigators, innovation, approach, and environment.”

Reference

Bayer launches Pulmonary Hypertension Accelerated Bayer (PHAB) Awards to help propel clinical advancements forward with up to 1 million dollars in grants [news release]. Whippany, NJ: Bayer; May 20, 2019.